Ricky w Johnstone

List of Publications by Year
in descending order

255 papers	30,768 citations	5248 83 h-index	4750 169 g-index
270 all docs	270 docs citations	270 times ranked	37987 citing authors

#	Article	IF	Citations
1	Targeting transcription cycles in cancer. Nature Reviews Cancer, 2022, 22, 5-24.	12.8	59
2	BET Inhibition Enhances TNF-Mediated Antitumor Immunity. Cancer Immunology Research, 2022, 10, 87-107.	1.6	8
3	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. Cancer Discovery, 2022, 12, 1560-1579.	7.7	13
4	Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. EMBO Molecular Medicine, 2022, 14, e15203.	3.3	10
5	Epigenetic modulators of B cell fate identified through coupled phenotype-transcriptome analysis. Cell Death and Differentiation, 2022, 29, 2519-2530.	5.0	5
6	Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood, 2021, 137, 2947-2957.	0.6	19
7	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITDâ€“Driven Acute Myeloid Leukemia. Cancer Discovery, 2021, 11, 1582-1599.	7.7	35
8	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells. Science Advances, 2021, 7, .	4.7	46
9	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. Clinical Cancer Research, 2021, 27, 4338-4352.	3.2	14
10	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular Cell, 2021, 81, 2183-2200.e13.	4.5	59
11	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. Cancer Discovery, 2021, 11, 2582-2601.	7.7	62
12	Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance. Nature Communications, 2021, 12, 2782.	5.8	20
13	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell, 2021, 184, 3143-3162.e32.	13.5	103
14	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 6222-6234.	3.2	17
15	Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses. International Journal of Radiation Oncology Biology Physics, 2021, 111, 502-514.	0.4	22
16	Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. Haematologica, 2021, 106, 2013-2017.	1.7	7
17	A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia, 2020, 34, 1646-1657.	3.3	54
18	AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. Clinical Cancer Research, 2020, 26, 6535-6549.	3.2	42

#	Article	IF	Citations
19	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. Cell Reports, 2020, 33, 108290.	2.9	4
20	Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia. Leukemia, 2020, 34, 3388-3392.	3.3	24
21	MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia. Blood Advances, 2020, 4, 4918-4923.	2.5	4
22	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. Molecular Therapy, 2020, 28, 2379-2393.	3.7	49
23	Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery, 2020, 19, 776-800.	21.5	264
24	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. Science Advances, 2020, 6, .	4.7	79
25	Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies. Journal of Immunology, 2020, 204, 2308-2315.	0.4	40
26	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. Cell Stem Cell, 2019, 25, 258-272.e9.	5.2	60
27	Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. Cell Reports, 2019, 28, 2784-2794.e5.	2.9	77
28	Joseph F. Sambrook (1939â€“2019). Nature Structural and Molecular Biology, 2019, 26, 846-847.	3.6	0
29	Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. Nature Communications, 2019, 10, 1347.	5.8	41
30	Antagonism of IAPs Enhances CAR T-cell Efficacy. Cancer Immunology Research, 2019, 7, 183-192.	1.6	68
31	Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer. Cell Death and Disease, 2018, 9, 442.	2.7	20
32	A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens. Methods in Molecular Biology, 2018, 1725, 201-227.	0.4	4
33	Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. Leukemia, 2018, 32, 237-241.	3.3	26
34	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications, 2018, 9, 5341.	5.8	356
35	Tumor immune evasion arises through loss of TNF sensitivity. Science Immunology, 2018, 3, .	5.6	244
36	Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature, 2018, 560, 253-257.	13.7	182

#	Article	IF	Citations
37	JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. Genes and Development, 2018, 32, 849-864.	2.7	26
38	Epigenetic control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK oligomerization. Cell Death and Differentiation, 2017, 24, 961-970.	5.0	52
39	HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia. Leukemia, 2017, 31, 995-997.	3.3	22
40	A chemical probe toolbox for dissecting the cancer epigenome. Nature Reviews Cancer, 2017, 17, 160-183.	12.8	76
41	A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia, 2017, 31, 1466-1470.	3.3	25
42	HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors. Cancer Research, 2017, 77, 2594-2606.	0.4	23
43	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	2.9	244
44	Genomic characterisation of EÎ¼-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene. Nature Communications, 2017, 8, 14581.	5.8	33
45	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood, 2017, 129, 2882-2895.	0.6	74
46	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research, 2017, 23, 2478-2490.	3.2	95
47	DOCK8 Drives Src-Dependent NK Cell Effector Function. Journal of Immunology, 2017, 199, 2118-2127.	0.4	18
48	Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leukemia and Lymphoma, 2017, 58, 996-998.	0.6	12
49	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation, 2017, 127, 929-941.	3.9	251
50	Serglycin determines secretory granule repertoire and regulates natural killer cell and cytotoxic T lymphocyte cytotoxicity. FEBS Journal, 2016, 283, 947-961.	2.2	31
51	Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell, 2016, 30, 59-74.	7.7	29
52	How do tumor cells respond to HDAC inhibition?. FEBS Journal, 2016, 283, 4032-4046.	2.2	97
53	In the Midst of Lifeâ€"Cell Death: What Is It, What Is It Good for, and How to Study It. Cold Spring Harbor Protocols, 2016, 2016, pdb.top070508.	0.2	1
54	The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. Oncogenesis, 2016, 5, e216-e216.	2.1	24

#	Article	IF	Citations
55	Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthetic Surgery Journal, 2016, 36, 782-783.	0.9	9
56	A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology, 2016, 34, 1010-1014.	9.4	66
57	Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the THâ€MYCN neuroblastoma mouse model. International Journal of Cancer, 2016, 139, 194-204.	2.3	22
58	Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica, 2016, 101, e387-e390.	1.7	124
59	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics, 2016, 15, 2030-2041.	1.9	57
60	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature, 2016, 538, 518-522.	13.7	159
61	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Science Translational Medicine, 2016, 8, 339ra69.	5.8	140
62	CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Research, 2016, 76, 3965-3977.	0.4	26
63	Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nature Structural and Molecular Biology, 2016, 23, 673-681.	3.6	92
64	Constitutive IFNÎ±/Î² signaling maintains expression of signaling intermediaries for efficient cytokine responses. Jak-stat, 2016, 5, e1173804.	2.2	2
65	The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. Cancer Research, 2016, 76, 1158-1169.	0.4	100
66	A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. Cell Death and Differentiation, 2016, 23, 1209-1218.	5.0	12
67	Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. Cancer Cell, 2016, 29, 145-158.	7.7	93
68	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. Cell Reports, 2016, 14, 1858-1866.	2.9	35
69	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. Cancer Discovery, 2016, 6, 59-70.	7.7	105
70	Scribble acts as an oncogene in EÎ¼-myc-driven lymphoma. Oncogene, 2016, 35, 1193-1197.	2.6	15
71	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. Oncotarget, 2016, 7, 49800-49818.	0.8	93
72	A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. Oncotarget, 2016, 7, 34582-34598.	0.8	13

#	Article	IF	Citations
73	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood, 2015, 126, 2392-2403.	0.6	48
74	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 2015, 75, 5228-5234.	0.4	270
75	CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia, 2015, 29, 1437-1441.	3.3	120
76	Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia. Clinical Epigenetics, 2015, 7, 2.	1.8	13
77	Manipulation of B-cell responses with histone deacetylase inhibitors. Nature Communications, 2015, 6, 6838.	5.8	73
78	BET inhibitor resistance emerges from leukaemia stem cells. Nature, 2015, 525, 538-542.	13.7	441
79	Letter to the Editor, â€œBET Inhibitor JQ1 Blocks Inflammation and Bone Destructionâ€. Journal of Dental Research, 2015, 94, 229-229.	2.5	2
80	New and emerging HDAC inhibitors for cancer treatment. Journal of Clinical Investigation, 2014, 124, 30-39.	3.9	1,137
81	Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. PLoS Pathogens, 2014, 10, e1004473.	2.1	437
82	Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. Current Opinion in Hematology, 2014, 21, 297-308.	1.2	8
83	Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. Bioinformatics, 2014, 30, 1064-1072.	1.8	75
84	The anticancer effects of HDAC inhibitors require the immune system. OncoImmunology, 2014, 3, e27414.	2.1	74
85	A functional genomics screen identifies PCAF and ADA3 as regulators of human granzyme B-mediated apoptosis and Bid cleavage. Cell Death and Differentiation, 2014, 21, 748-760.	5.0	15
86	Fas ligandâ€“mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nature Medicine, 2014, 20, 283-290.	15.2	79
87	From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma. Cancer Cell, 2014, 25, 9-11.	7.7	26
88	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood, 2014, 123, 1341-1352.	0.6	107
89	The Curative Outcome of Radioimmunotherapy in a Mouse Breast Cancer Model Relies on mTOR Signaling. Radiation Research, 2014, 182, 219.	0.7	29
90	Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. Cancer Discovery, 2014, 4, 423-433.	7.7	242

#	Article	IF	Citations
91	The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the EÎ¼-myc model of B-cell lymphoma. Oncogene, 2014, 33, 5415-5423.	2.6	43
92	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nature Reviews Drug Discovery, 2014, 13, 673-691.	21.5	1,277
93	The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound. Cell Reports, 2014, 7, 1009-1019.	2.9	34
94	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. Leukemia Research, 2014, 38, 948-954.	0.4	14
95	Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat. Scientific Data, 2014, 1, 140017.	2.4	14
96	Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood, 2014, 123, 725-733.	0.6	59
97	Id2 represses E2A-mediated activation of IL-10 expression in T cells. Blood, 2014, 123, 3420-3428.	0.6	23
98	Lethal Giant Larvae 1 Tumour Suppressor Activity Is Not Conserved in Models of Mammalian T and B Cell Leukaemia. PLoS ONE, 2014, 9, e87376.	1.1	17
99	Modulation of antitumour immune responses by intratumoural Stat1 expression. Immunology and Cell Biology, 2013, 91, 556-567.	1.0	11
100	Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors. Cell Reports, 2013, 5, 1047-1059.	2.9	116
101	Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide. Thrombosis Research, 2013, 131, 514-520.	0.8	9
102	Development of targeted therapies for acute myeloid leukemias. Experimental Hematology, 2013, 41, S49.	0.2	0
103	An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors. Cancer Research, 2013, 73, 7265-7276.	0.4	112
104	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. European Journal of Cancer, 2013, 49, 3936-3944.	1.3	72
105	<scp>AKT</scp> signalling is required for ribosomal <scp>RNA</scp> synthesis and progression of <scp>E</scp>Î¼â€Myc <scp>B</scp>â€cell lymphoma inÂvivo. FEBS Journal, 2013, 280, 5307-5316.	2.2	19
106	The mTORC1 Inhibitor Everolimus Prevents and Treats EÎ¼-Myc Lymphoma by Restoring Oncogene-Induced Senescence. Cancer Discovery, 2013, 3, 82-95.	7.7	58
107	Cyclin-dependent kinase inhibitor, dinaciclib induces anti-tumour activity of MLL-AF9 in vivo mouse models. Experimental Hematology, 2013, 41, S53.	0.2	0
108	Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene, 2013, 32, 4191-4202.	2.6	74

#	Article	IF	Citations
109	HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death and Disease, 2013, 4, e519-e519.	2.7	150
110	Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. Molecular Cancer Therapeutics, 2013, 12, 2709-2721.	1.9	45
111	Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2â€²-Deoxycytidine in Solid Tumor Cells. Molecular Cancer Therapeutics, 2013, 12, 2226-2236.	1.9	81
112	Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death and Disease, 2013, 4, e798-e798.	2.7	32
113	Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood, 2013, 121, 2964-2974.	0.6	59
114	A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood, 2013, 121, 3459-3468.	0.6	106
115	Regulating the TRAIL of Destruction: How A20 Protects Glioblastomas from TRAIL-Mediated Death: Figure 1.. Cancer Discovery, 2012, 2, 112-114.	7.7	10
116	Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies. Cancer Research, 2012, 72, 3163-3174.	0.4	248
117	Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies. OncoImmunology, 2012, 1, 1629-1631.	2.1	13
118	The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. OncoImmunology, 2012, 1, 377-379.	2.1	14
119	Granzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737. Cell Death and Disease, 2012, 3, e344-e344.	2.7	18
120	PIDDosome-independent tumor suppression by Caspase-2. Cell Death and Differentiation, 2012, 19, 1722-1732.	5.0	60
121	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death and Disease, 2012, 3, e409-e409.	2.7	42
122	Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene, 2012, 31, 1661-1672.	2.6	127
123	Intrinsic and Extrinsic Apoptotic Pathway Signaling as Determinants of Histone Deacetylase Inhibitor Antitumor Activity. Advances in Cancer Research, 2012, 116, 165-197.	1.9	101
124	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood, 2012, 120, 822-832.	0.6	50
125	Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood, 2012, 120, 376-385.	0.6	174
126	NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood, 2012, 120, 3019-3029.	0.6	67

#	Article	IF	Citations
127	Oncogenes in Cell Survival and Cell Death. Cold Spring Harbor Perspectives in Biology, 2012, 4, a009829-a009829.	2.3	99
128	Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors. Cell Death and Disease, 2012, 3, e387-e387.	2.7	9
129	Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling. Immunity, 2012, 36, 166-174.	6.6	372
130	Structures of the HIN Domain:DNA Complexes Reveal Ligand Binding and Activation Mechanisms of the AIM2 Inflammasome and IFI16 Receptor. Immunity, 2012, 36, 561-571.	6.6	456
131	A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax^{Â®}). Epigenomics, 2012, 4, 571-589.	1.0	39
132	Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro. Leukemia, 2012, 26, 1433-1435.	3.3	2
133	Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. Cancer Cell, 2012, 22, 51-65.	7.7	468
134	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. Journal of Clinical Investigation, 2012, 122, 553-557.	3.9	174
135	Promises and challenges of anticancer drugs that target the epigenome. Epigenomics, 2011, 3, 547-565.	1.0	21
136	Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitorâ€“induced thrombocytopenia. Blood, 2011, 117, 3658-3668.	0.6	128
137	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood, 2011, 118, 6274-6283.	0.6	83
138	MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). Annals of Hematology, 2011, 90, 847-849.	0.8	13
139	Antitumor activities and onâ€target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. International Journal of Cancer, 2011, 128, 2735-2747.	2.3	11
140	In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer. Molecular Cancer Therapeutics, 2011, 10, 1440-1449.	1.9	70
141	Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4141-4146.	3.3	98
142	Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737. Cancer Research, 2011, 71, 3603-3615.	0.4	51
143	AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer. Science Signaling, 2011, 4, ra56.	1.6	126
144	Inducible activation of IFI 16 results in suppression of telomerase activity, growth suppression and induction of cellular senescence. Journal of Cellular Biochemistry, 2010, 109, 103-112.	1.2	13

#	Article	IF	Citations
145	Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Investigational New Drugs, 2010, 28, 3-20.	1.2	123
146	Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals, 2010, 3, 2674-2688.	1.7	7
147	Asymmetric Cell Division of T Cells upon Antigen Presentation Uses Multiple Conserved Mechanisms. Journal of Immunology, 2010, 185, 367-375.	0.4	117
148	Functional Crosstalk between Type I and II Interferon through the Regulated Expression of STAT1. PLoS Biology, 2010, 8, e1000361.	2.6	134
149	SnapShot: Extrinsic Apoptosis Pathways. Cell, 2010, 143, 1192-1192.e2.	13.5	68
150	Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncology, 2009, 5, 601-612.	1.1	119
151	Perforin-mediated suppression of B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2723-2728.	3.3	40
152	Rational Combinations Using HDAC Inhibitors. Clinical Cancer Research, 2009, 15, 3970-3977.	3.2	207
153	Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Letters, 2009, 280, 125-133.	3.2	199
154	Epigenetics in cancer: Targeting chromatin modifications. Molecular Cancer Therapeutics, 2009, 8, 1409-1420.	1.9	435
155	Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood, 2009, 113, 1982-1991.	0.6	73
156	The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood, 2009, 114, 380-393.	0.6	108
157	Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors. PLoS ONE, 2009, 4, e4482.	1.1	57
158	Cloning and characterisation of Ifi206: A new murine HINâ€200 family member. Journal of Cellular Biochemistry, 2008, 103, 1270-1282.	1.2	9
159	The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Reviews Cancer, 2008, 8, 782-798.	12.8	788
160	Blocking granule-mediated death by primary human NK cells requires both protection of mitochondria and inhibition of caspase activity. Cell Death and Differentiation, 2008, 15, 708-717.	5.0	34
161	IFNÎ³ signalingâ€"Does it mean JAKâ€"STAT?. Cytokine and Growth Factor Reviews, 2008, 19, 383-394.	3.2	292
162	Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11317-11322.	3.3	129

#	Article	IF	Citations
163	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. Clinical Cancer Research, 2008, 14, 4500-4510.	3.2	286
164	Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Molecular Cancer Therapeutics, 2008, 7, 1066-1079.	1.9	63
165	The Role of p202 in Regulating Hematopoietic Cell Proliferation and Differentiation. Journal of Interferon and Cytokine Research, 2008, 28, 5-11.	0.5	11
166	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16254-16259.	3.3	45
167	Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Review of Anticancer Therapy, 2008, 8, 413-432.	1.1	89
168	Epigenetic Drugs. , 2008, , 49-71.		0
169	Epigenetic Drugs Histone Deacetylase Inhibitors. , 2008, , 49-71.		0
170	Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19512-19517.	3.3	611
171	Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Review of Anticancer Therapy, 2007, 7, 1439-1449.	1.1	38
172	A Novel c-Jun-dependent Signal Transduction Pathway Necessary for the Transcriptional Activation of Interferon Î³ Response Genes. Journal of Biological Chemistry, 2007, 282, 938-946.	1.6	52
173	The BH3-Only Protein Bid Is Dispensable for DNA Damage- and Replicative Stress-Induced Apoptosis or Cell-Cycle Arrest. Cell, 2007, 129, 423-433.	13.5	189
174	Response: Does Bid Play a Role in the DNA Damage Response?. Cell, 2007, 130, 10-11.	13.5	14
175	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8071-8076.	3.3	195
176	Histone deacetylase inhibitors in cancer therapy. Expert Opinion on Investigational Drugs, 2007, 16, 659-678.	1.9	193
177	From cancer immunosurveillance to cancer immunotherapy. Immunological Reviews, 2007, 220, 82-101.	2.8	78
178	Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 2006, 5, 769-784.	21.5	2,578
179	Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene, 2005, 24, 8061-8075.	2.6	184
180	Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3697-3702.	3.3	504

#	Article	IF	Citations
181	A Central Role for Bid in Granzyme B-induced Apoptosis. Journal of Biological Chemistry, 2005, 280, 4476-4482.	1.6	111
182	The HIN-200 family: More than interferon-inducible genes?. Experimental Cell Research, 2005, 308, 1-17.	1.2	152
183	Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2. Biochemical and Biophysical Research Communications, 2005, 326, 417-424.	1.0	41
184	Histone-Deacetylase Inhibitors for the Treatment of Cancer. Cell Cycle, 2004, 3, 777-786.	1.3	127
185	The multidrug resistance gene mdr1a influences resistance to ectromelia virus infection by mechanisms other than conventional immunity. Immunology and Cell Biology, 2004, 82, 462-470.	1.0	6
186	Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death and Differentiation, 2004, 11, 1028-1037.	5.0	93
187	Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene, 2004, 23, 6693-6701.	2.6	129
188	Growth Suppressors IFI-204 and IFI-205 Inhibit Primitive Hematopoietic Cell Proliferation In Vitro and in Vivo.. Blood, 2004, 104, 1691-1691.	0.6	0
189	Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle, 2004, 3, 779-88.	1.3	41
190	Suberanilohydroxamic Acid. Aton Pharma. IDrugs: the Investigational Drugs Journal, 2004, 7, 674-82.	0.7	2
191	Expression of IFIÂ16 in epithelial cells and lymphoid tissues. Histochemistry and Cell Biology, 2003, 119, 45-54.	0.8	59
192	A role for P-glycoprotein in regulating cell growth and survival. Clinical and Applied Immunology Reviews, 2003, 4, 31-47.	0.4	14
193	Histone deacetylase inhibitors in cancer therapy. Cancer Cell, 2003, 4, 13-18.	7.7	451
194	Critical role of the transcription factor AP-1 for the constitutive and interferon-induced expression of IFI 16. Journal of Cellular Biochemistry, 2003, 89, 80-93.	1.2	23
195	A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway. Oncogene, 2003, 22, 8931-8938.	2.6	108
196	Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene, 2003, 22, 4831-4840.	2.6	104
197	Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif. Molecular and Cellular Biology, 2003, 23, 6520-6532.	1.1	64
198	Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Research, 2003, 63, 4460-71.	0.4	183

#	Article	IF	Citations
199	Human Immunodeficiency Virus Type 1 Nef Binds to Tumor Suppressor p53 and Protects Cells against p53-Mediated Apoptosis. Journal of Virology, 2002, 76, 2692-2702.	1.5	113
200	Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress. Current Cancer Drug Targets, 2002, 2, 337-353.	0.8	25
201	P-glycoprotein as a General Antiapoptotic Protein. , 2002, , 433-441.		0
202	Apoptosis. Cell, 2002, 108, 153-164.	13.5	2,122
203	Deamidation of Bcl-XL. Molecular Cell, 2002, 10, 695-697.	4.5	8
204	Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. International Journal of Cancer, 2002, 99, 292-298.	2.3	72
205	Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. British Journal of Haematology, 2002, 119, 965-969.	1.2	39
206	P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death and Differentiation, 2002, 9, 1266-1272.	5.0	74
207	Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews Drug Discovery, 2002, 1, 287-299.	21.5	1,335
208	Wilms Tumor Suppressor WT1. , 2002, , 543-551.		0
209	The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10833-10838.	3.3	468
210	Novel properties of the protein kinase CK2-site-regulated nuclear- localization sequence of the interferon-induced nuclear factor IFI 16. Biochemical Journal, 2001, 353, 69-77.	1.7	44
211	Dissecting the apoptotic mechanisms of chemotherapeutic drugs and lymphocytes to design effective anticancer therapies. Drug Development Research, 2001, 52, 549-557.	1.4	3
212	Functional Analysis of the Leukemia Protein ELL: Evidence for a Role in the Regulation of Cell Growth and Survival. Molecular and Cellular Biology, 2001, 21, 1672-1681.	1.1	33
213	P-glycoprotein Does Not Protect Cells against Cytolysis Induced by Pore-forming Proteins. Journal of Biological Chemistry, 2001, 276, 16667-16673.	1.6	26
214	Novel properties of the protein kinase CK2-site-regulated nuclear- localization sequence of the interferon-induced nuclear factor IFI 16. Biochemical Journal, 2000, 353, 69.	1.7	7
215	Role of TNF in lymphocyte-mediated cytotoxicity. Microscopy Research and Technique, 2000, 50, 196-208.	1.2	48
216	Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene, 2000, 19, 6033-6042.	2.6	95

#	Article	IF	Citations
217	Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends in Biochemical Sciences, 2000, 25, 1-6.	3.7	301
218	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood, 2000, 95, 2378-2385.	0.6	76
219	Filamin (280-kDa Actin-binding Protein) Is a Caspase Substrate and Is Also Cleaved Directly by the Cytotoxic T Lymphocyte Protease Granzyme B during Apoptosis. Journal of Biological Chemistry, 2000, 275, 39262-39266.	1.6	79
220	Identification, Cloning, Expression, and Biochemical Characterization of the Testis-specific RNA Polymerase II Elongation Factor ELL3. Journal of Biological Chemistry, 2000, 275, 32052-32056.	1.6	66
221	Initiation of Apoptosis by Granzyme B Requires Direct Cleavage of Bid, but Not Direct Granzyme Bâ€“Mediated Caspase Activation. Journal of Experimental Medicine, 2000, 192, 1403-1414.	4.2	331
222	A Role for P-Glycoprotein in Regulating Cell Death. Leukemia and Lymphoma, 2000, 38, 1-11.	0.6	105
223	Equivalent Death of P-Glycoprotein Expressing and Nonexpressing Cells Induced by the Protein Kinase C Inhibitor Staurosporine. Biochemical and Biophysical Research Communications, 2000, 276, 231-237.	1.0	13
224	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood, 2000, 95, 2378-2385.	0.6	25
225	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. Blood, 1999, 93, 1075-1085.	0.6	288
226	Structural organization, tissue expression, and chromosomal localization of Ciao 1, a functional modulator of the Wilms' tumor suppressor, WT1. Immunogenetics, 1999, 49, 900-905.	1.2	1
227	Transcription and Growth Regulatory Functions of the HIN-200 Family of Proteins. Molecular and Cellular Biology, 1999, 19, 5833-5838.	1.1	115
228	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. Blood, 1999, 93, 1075-1085.	0.6	16
229	Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. Journal of Immunology, 1999, 163, 1350-3.	0.4	33
230	The question begs â€" what is the role of P-glycoprotein in normal physiology?. Drug Resistance Updates, 1998, 1, 340-342.	6.5	0
231	Isotypic Variants of the Interferon-Inducible Transcriptional Repressor IFI 16 Arise through Differential mRNA Splicingâ€. Biochemistry, 1998, 37, 11924-11931.	1.2	55
232	Mapping of the Human PAWR (par-4) Gene to Chromosome 12q21. Genomics, 1998, 53, 241-243.	1.3	48
233	Ciao 1 Is a Novel WD40 Protein That Interacts with the Tumor Suppressor Protein WT1. Journal of Biological Chemistry, 1998, 273, 10880-10887.	1.6	60
234	The Human Interferon-inducible Protein, IFI 16, Is a Repressor of Transcription. Journal of Biological Chemistry, 1998, 273, 17172-17177.	1.6	72

#	Article	IF	Citations
235	The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 7024-7029.	3.3	328
236	The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and markedly down-regulated in other myeloid precursor populations. Journal of Leukocyte Biology, 1998, 64, 546-554.	1.5	37
237	Fas Ligand-Mediated Lysis of Self Bystander Targets by Human Papillomavirus-Specific CD8⁺Cytotoxic T Lymphocytes. Journal of Virology, 1998, 72, 5948-5954.	1.5	23
238	Expression and Function of the Leucine Zipper Protein Par-4 in Apoptosis. Molecular and Cellular Biology, 1997, 17, 3823-3832.	1.1	191
239	Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene, 1997, 15, 453-457.	2.6	238
240	A Novel Repressor, par-4, Modulates Transcription and Growth Suppression Functions of the Wilmsâ€™ Tumor Suppressor WT1. Molecular and Cellular Biology, 1996, 16, 6945-6956.	1.1	246
241	Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59. Transplantation Proceedings, 1994, 26, 1070-1.	0.3	6
242	Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing. Molecular Immunology, 1993, 30, 1231-1241.	1.0	95
243	Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis. Transplant Immunology, 1993, 1, 101-108.	0.6	49
244	Identification and quantification of complement regulator CD46 on normal human tissues. Immunology, 1993, 79, 341-7.	2.0	88
245	CD46 (MCP) confers protection from lysis by xenogeneic antibodies. Transplantation Proceedings, 1993, 25, 396-7.	0.3	4
246	Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation. Journal of Neuroimmunology, 1992, 36, 199-208.	1.1	49
247	Strong associations between RFLP and protein polymorphisms for CD46. Immunogenetics, 1992, 36, 79-85.	1.2	21
248	Functional characterisation of alternatively spliced CD46 cytoplasmic tails. Transplantation Proceedings, 1992, 24, 2329-30.	0.3	11
249	Tissue-specific expression of CD46 isoforms. Transplantation Proceedings, 1992, 24, 2331-2.	0.3	4
250	Molecular characterization of the polymorphic expression of CD46: a cell surface molecule protecting cells from complement attack. Transplantation Proceedings, 1992, 24, 211-3.	0.3	3
251	Identification of four different CD46 (MCP) molecules with anti-peptide antibodies. Biochemical and Biophysical Research Communications, 1991, 180, 1091-1097.	1.0	10
252	The effect of temperature on the binding kinetics and equilibrium constants of monoclonal antibodies to cell surface antigens. Molecular Immunology, 1990, 27, 327-333.	1.0	64

#	Article	IF	Citations
253	Comparison of in vitro cell binding characteristics of four monoclonal antibodies and their individual tumor localization properties in mice. Cancer Research, 1990, 50, 4423-8.	0.4	15
254	Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM1899). Cancer Research, 1990, 50, 5225-30.	0.4	18
255	The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. Frontiers in Oncology, 0, 12, .	1.3	8